Summit Therapeutics Share Discussion Threads

[hugus maximus] 13/11/2017 19:12

Thanks Dalcon01 ... "The conference brings together families living with Duchenne and Becker muscular dystrophy, along with experts and industry members aiming to treat these diseases."

So this conference also involves Becker Muscular Dystrophy. I remember an AGM a few years ago when the subject arose of whether the same approach with Utrophin modulation might indeed work with Becker MD? At the time, there was very much a modus operandi, focusing resources on the principle of proving a fix for Duchenne, however I assume that if EZT is shown to work with Duchenne, there's no reason why Becker MD(which has approximately the same number of sufferers world wide)shouldn't be looked at with the same treatment?

Please someone correct me if I'm wrong, but I've not read anything that suggest's Sarepta's Exondys 51 holds a potential way forward for Becker MD?

[dalcon01] 13/11/2017 18:44

Apologies if you've seen this but just seen it on a new thread that's been opened?

arnu gutierrez
  12 Nov '17 - 02:48   0   0
Summit Therapeutics Sees Utrophin Modulation as a Potential Universal Treatment Option in Duchenne muscular dystrophy

[chrisatrdg] 13/11/2017 17:42

Per gmcc this evening from the other board:

'DMD utrophin

FYI :

For folks who have not come across utrophin modulators nice simple explanation !

£Michelle Avery, PhD Director, Investor Relations at Summit Therapeutics plc
Dated 28/10/2017

£R: It is very exciting work. We are hoping this is, like, the first trial that lets us know whether or not this has a chance to work in patients, and we are really, really hopefull It seems like it makes sense from a scientific perspective.

Good luck DMD community'

[waterloo01] 13/11/2017 16:19

Volume and price looking good on Nasdaq. Will it shoot through $12.00 or is that resistance?

[hugus maximus] 13/11/2017 11:20

Morning Chris - IMO - any conjecture here could also be fuelled by the fact that if EZT proves to be a success next year, Sarepta in their current agreement have to stump up a further $500M in part payments .. simply in order to maintain the EU rights! By comparison a deal now, whilst Summit's share price is so low would be daylight robbery.

[chrisatrdg] 13/11/2017 10:12

Good start to the day lets hope the share price will increase further but it still has a long way to go before getting back to where we were.

Interesting posts recently on why Serepta is increasing what is seen as a 'war chest' not sure they will go for a Buy for Summit as I think they already have what they want from us for now.

[arnu gutierrez] 12/11/2017 02:48

Summit Therapeutics Sees Utrophin Modulation as a Potential Universal Treatment Option in Duchenne muscular dystrophy

[hugus maximus] 11/11/2017 10:48

Thanks for that Chris.

Whatever is or isn't going on at Sarepta ... it would be nice to see some improvement in the share price before the 15th, when they gather together their booty.

Some folk on the Sarepta Yahoo Finance and SeekingAlpha message boards in the USA are certainly aware of this connection and one assumes conjecture will move the share price a little north, as American investors start to have the same conversations we're having.

EDIT - Question that I put on Sarepta's YF BB enquiring to the connection with their cash hoard and Summit's DMD work, has just been 'liked' 15 times. (4 dislikes ... but then that's almost 20 aware of the notion!)

Following yesterday's SeekingAlpha article about Sarepta (see Luminoso link above) the following blog has a note from "DoublePlusGood":

10 Nov 2017, 02:21 PM Message - "Agree on Summit and took profit on Sarepta while increasing my Summit holding"

[chrisatrdg] 10/11/2017 20:27

For those on twitter the following account shows the tweets on todays C-Diff conference & includes tweets from Summit.Some of you with some better understanding of the science behind C-Diff may find the various tweets of interest.

#CDiff2017

[waterloo01] 10/11/2017 20:11

Decent volume on Nasdaq, about 700,000 shares in AIM terms. Bodes well.

[waterloo01] 10/11/2017 17:07

Assuming it might be a larger pharma, they tend to want WW rights, also as SRPT are funding 45% of future research, it would further complicate it. IMO

[hugus maximus] 10/11/2017 16:52

Interesting thought Waterloo ... you suggest that the existing EU / South America set-up with SRPT may put off others?

[waterloo01] 10/11/2017 16:28

except...I think the SRTP deal also will act like a poison pill as far as any suitor is concerned. RDZ is a different issue.

[hugus maximus] 10/11/2017 16:23

And ... if you were Mr Ingram - CEO of Sarepta,(To quote Waterloo "determined to be THE company dealing with DMD, regardless of approach") wouldn't you be concerned that a large phama might appear in the T/O frame ... if there's ANY hint of "proof of concept" at the 24 wk results, surely Sarepta have to be well in advance of any posse!?

[waterloo01] 10/11/2017 14:42

Suspect some on Nasdaq share my view. I've said a number of times of late that we really shouldn't be trading below $12.00 and if anything should be testing the previous highs.

[luminoso] 10/11/2017 14:34

True, waterloo. Meanwhile opening bell at nasdaq seeing correlation of the wrong sort this time. Ha ! Off out for a walk on the beach and clear my head.

[waterloo01] 10/11/2017 14:22

Do they need to wait for the results? As it's an open label trial and with the 'alliance' they are sharing data/research, they 'might' already have an insight, enough anyhow to make a move either way.

[luminoso] 10/11/2017 14:18

With their clout in Washington and their PR machine, they would bull up even fairly mediocre P2 results and I can imagine them finding it easier to get a quicker approval for EZT down the road, if it was all theirs.

[luminoso] 10/11/2017 14:13

SRPT may have to work out the equation in next few weeks.
EZT now, while its unproven and cheap - or after P2 data, when it will be very much more expensive, IF successful.
With their other irons in the fire likely to drain their cash hoard next year, I would not be surprised to see them act sooner rather than later, where EZT is concerned.

[waterloo01] 10/11/2017 13:56

The deal last time was done a few days/weeks after SRPT got approvals and it's well within reason to think they might just make an early move for worldwide rights and effective ownership, as they seem determined to be THE company dealing with DMD, regardless of approach.

Either way, and as ever......the next few months are rather important and it wouldn't surprise me if we've seen our last AGM, for obvious reasons.

[hugus maximus] 10/11/2017 13:29

Adding even further to the conspiracy of disinterest from all things Sarepta ... why when Sarepta said that concerns over a Quarter Loss was OK "due to them purchasing a DMD license from Summit", is this collaboration no longer mentioned?(To keep the Summit share price cheap?)

CNBC NEWS 1st March 2017
"Sarepta Therapeutic shares waver amid concerns over 2017 guidance? The muscular dystrophy drug developer reported a fourth-quarter loss of $1.62 per share on revenue of $5.42 million.

Sarepta said the loss for the quarter was primarily driven by an expense recorded in connection with Summit Therapeutics, to which Sarepta paid $40 million for a licensing agreement.

Summit and Sarepta entered into the collaboration agreement late last year, which granted Sarepta rights in Europe to Summit's drug pipeline, according to a news release."

[phowdo] 10/11/2017 13:11

A bid at 250p would probably do it.

[hugus maximus] 10/11/2017 12:54

Interesting notion Luminoso ...

QUESTION: At this point in time, why might someone wish to see this company with its lowest share price in a long time?

ANSWER: Because that someone wants to buy the company as cheaply as possible.

Don't you just love a good conspiracy theory?

But sssh ... let's not bring up any connection with Summit to Sarepta shareholders.

[luminoso] 10/11/2017 11:08

It just seems strange that an article by a self confessed Long shareholder in SRPT should not mention the agreement with Smmt and the possible triggering of further investment in Smmt as milestones are passed, etc, when he is discussing the future of SRPT. He has not even dismissed Utrophin modulation as a side show to their other projects. He must be aware of the deal with Smmt, but has chosen not to mention it. Perhaps I am seeing too much in that, but clearly any mention of Smmt in connection with the war chest would alert US traders to the possibility of buying into a potential target and thereby making the potential target more expensive. Just musings, IMO.

[hugus maximus] 10/11/2017 10:41

Interesting .... $618 Million "cash hoard".

I realise there maybe creative invention going on amongst some of us, but whether or not Sarepta are building a war chest for Summit, it just goes to show that NASDAQ investors still don't recognise any serious potential for this company's DMD drug.

At a point so close to Summit's first DMD P2 progress report, there would certainly be a faster uptake of Summit shares in the states (especially at these prices,) but clearly not many NASDAQ folk yet see the possibility of Sarepta's need to own Summit.

If Summit show any sign of proof of concept with Utrophin Modulation, it will blow everything else that Sarepta are involved with out of the water.

I've been on the Seeking Alpha list to receive notes about Sarepta for some time, and it's intriguing how Summit is never mentioned. (Even if for no other reason than, Sarepta have a Europe / South America license for EZD)